Matinas BioPharma agrees to sell Nanotechnologies unit to Azurity for USD 4 million upfront

Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc.

MTNB

0.00
  • Matinas BioPharma agreed to combine with GH Power to form a NYSE-listed clean energy and critical minerals company focused on modular reactor systems.
  • GH Power holders are expected to own about 91% of the combined company on a fully diluted basis; Matinas holders about 9%.
  • Matinas shares are expected to convert into the right to receive 0.1 share of the new parent company at closing.
  • Separately, Azurity Pharmaceuticals agreed to buy Matinas BioPharma Nanotechnologies, including MAT2203 and the LNC platform, for USD 4 million upfront.
  • The Azurity deal includes up to USD 17.5 million in milestones, mid-single-digit royalties, and targets a fourth-quarter 2026 close alongside the GH Power combination.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Matinas BioPharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-032938), on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.